Researchers have engineered gold-based molecules that target cancer cells and leave healthy cells unharmed, in a critical step towards precision cancer drugs with fewer toxic side effects.
Pre-clinical studies have shown the molecules were up to 24 times more effective at killing cancer cells than the widely used anti-cancer drug cisplatin and were also better at inhibiting tumour growth.
The molecules were also more targeted and selective, making them promising candidates for development into a new class of gold-based drugs that can wipe out the cancer without destroying healthy cells.
Significantly, the synthetic molecules are built with resistance-fighting features to keep them effective over time, unlike current chemotherapies.
The study by researchers at RMIT University, detailing four new bio-active molecules and their effectiveness against five types of cancer cells, is published in Chemistry – A European Journal.
Dr Neda Mirzadeh, co-leader of the Molecular Engineering Group at RMIT, said the limitations of commonly used metal-based chemotherapies drove a need to find better alternatives.
“We’ve made huge inroads in cancer treatment over recent decades, but the disease still kills over 9.6 million people globally each year and remains the world’s second leading cause of death,” Mirzadeh said.
“While metal-based drugs have successfully pushed survival rates up, their effectiveness is limited because of toxic side effects, drug resistance and poor stability.
“The gold-based molecules we’ve designed are far more selective and stable.
“Our results show there’s incredible potential here for the development of new cancer-fighting therapeutics that can deliver lasting power and precision.”
The molecules were evaluated in pre-clinical tests and found to be highly cytotoxic against prostate, breast, cervical, melanoma and colon cancer cells. Animal trials showed treatment with the molecules significantly inhibited tumour growth (up to 46.9%, compared with 29% for cisplatin).
The gold-based compounds also inhibit the action of an enzyme found in cancer cells, thioredoxin reductase, that is linked with cancer progression and the development of drug resistance.
In addition, the molecules have strong anti-inflammatory properties, giving them a dual therapeutic effect and potential application in the treatment of chronic inflammatory conditions like arthritis.
Molecular design pioneers
Part of RMIT’s Centre for Advanced Materials and Industrial Chemistry (CAMIC), the Molecular Engineering Group brings together synthetic chemists with pharmacologists and has over two decades of expertise in designing gold molecules for practical applications.
The pioneering group, one of just a few in the world focusing on the medical potential of gold-based molecules, has had two patents awarded for their work to date.
Team leader and CAMIC Director, Distinguished Professor Suresh Bhargava, said gold had an ancient history of medical use, particularly in India and China.
“We know that gold is readily accepted by the human body and we know it has been used for thousands of years in treating various conditions,” Bhargava said.
“Essentially, gold has been market tested, but not scientifically validated.
“Our work is helping both provide the evidence base that’s missing, as well as delivering new families of molecules that are tailor-made to amplify the natural healing properties of gold.”
For Bhargava, who has lost close friends to cancer, the search for new and better treatments is a personal passion.
“I saw friends go through many years of treatment before they died and I saw how the side effects they experienced were almost more painful than the cancer itself,” he said.
“At the time there was no alternative but scientists have recently started to explore the potential of gold-based drugs and I realised this was our opportunity.
“We used the power of collective intelligence to bring together synthetic chemists and pharmacologists to address the issue.”
Bhargava has been invited to join the prestigious International Health Industry Forum and will speak on the gold medicine research at its annual meeting in Yantai, China (20-23 September).
“It’s a big challenge to be solved but all the great medical breakthroughs start from somewhere, and each step brings us closer to our goal of translating our research to make a sustained and lasting impact on the world.”
The research team has completed successful in vitro and in vivo pre-clinical studies and is seeking funding to support the next stage of the research – clinical studies and regulatory approval.
The Latest on: Precision cancer drugs
via Google News
The Latest on: Precision cancer drugs
- Automated Microscopy Market - Actionable Research on COVID-19 | Demand for Drug Discovery to Treat Cancer to Boost the Market Growth | Technavioon October 7, 2020 at 12:45 pm
Technavio has announced its latest market research report titled Global Automated Microscopy Market 2020-2024 (Graphic: ) The prevalence of cancer is increasing across the world. As a result, there is ...
- Development of precision drug delivery tool to treat traumatic brain injuryon October 7, 2020 at 5:42 am
An interdisciplinary team of researchers at the University of Southern California has developed a precision drug delivery tool to selectively treat areas of the brain damaged during a traumatic brain ...
- Mysterious molecular phenomenon could boost precision of targeted drug deliveryon October 6, 2020 at 6:39 am
A growing area of medicine looks at how cellular binding observed in nature—where molecules like viruses or proteins bind to specific receptors on a cell—can be mimicked to aid drug delivery.
- Concentrating and Releasing Drugs in the Brain with Pinpoint Accuracyon October 5, 2020 at 1:00 pm
Scientists at ETH Zurich say they have developed a technique for concentrating and releasing drugs in the brain with much accuracy. This could make it possible in the future to deliver psychiatric and ...
- $50K Grant Supports Exploration of Treatment for Liver Canceron October 5, 2020 at 11:11 am
One of your neighbors posted in Health & Fitness. Click through to read what they have to say. (The views expressed in this post are the author’s own.) ...
- Precision Medicine Treatments Improve Cancer Patient Outcomeson October 5, 2020 at 10:02 am
Using individual patients' molecular tumor makeups, researchers designed precision medicine strategies to improve outcomes for cancer patients.
- Millimetre-precision drug delivery to the brainon October 5, 2020 at 9:47 am
Researchers at ETH Zurich have developed a method for concentrating and releasing drugs in the brain with pinpoint accuracy. This could make it possible in the future to deliver psychiatric and cancer ...
- Bristol-Myers Squibb to buy Peninsula heart drug maker for $13.1 billionon October 5, 2020 at 6:10 am
An early post-recession bet on precision heart drugs will pay off with a $13.1 billion purchase of Brisbane's MyoKardia Inc. by drug giant Bristol-Myers Squibb Co. The $225-per-share offer by ...
- Precision cancer drug targets DNA repairon October 4, 2020 at 5:00 pm
A new anti-tumour drug that prevents cancer cells from repairing their DNA shows promising results in an early-stage clinical trial. The purpose of this drug, BAY1895344, is to inhibit the DNA repair ...
- Targeting DNA Repair Shows Potential in Advanced Cancer Therapyon September 30, 2020 at 5:00 am
Scientists in the U.K. report that a new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial, highlighting the potential of a new class of drugs ...
via Bing News